IMNM (Immunome Inc) Net Profit

IMNM (Immunome) - company brandmark

Immunome, Inc. (IMNM) leverages the body's own defense mechanisms to identify new tumor antibodies, establishing a foundation for long-term collaboration with industry leaders. The company is currently focusing on expanding its portfolio of targeted therapies and accelerating primary molecule testing. The implementation of robotic B-cell analysis stations eliminates routine labor, while the profit metric stands at -0.25. The confirmed price history on the GURU.Markets chart clearly visualizes these processes.

IMNM (Immunome, Inc.) Net Profit history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Immunome (IMNM)

- price and consensus price forecast:
Stock Quotes Immunome Bio|IMNM - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Immunome Bio|IMNM - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Immunome|IMNM - Book Capitalization|Market Capitalization to Book Value immunome.com|IMNM - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Immunome, Inc.|IMNM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Immunome Inc|IMNM - Company Total Debt|Debts to Book Capitalization Immunome Bio|IMNM - Company Long-Term Debt|Company Short-Term Indebtedness Immunome|Immediate Liquidity immunome.com
- net income and valuation multiples indicators:
IMNM - Net Profit
Summary company analysis:Immunome, Inc.
Core merchandise of Immunome Corp

The scale of Immunome, Inc. (IMNM) operations is determined by the intensity of the development of targeted drugs and radioligands. This indicator captures the daily inflow of funds, promptly reflecting the impact of macroeconomics on the financial result. The metric measures real operating benefit, excluding temporary reporting gaps. For R&D companies, such price action confirms the efficiency of the clinical pipeline. By analyzing the company's net profit, an investor can assess the risk of overpaying when purchasing the asset at its peak.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|Net Financial Result Pharming Corp PHAR|Nektar Therapeutics (NKTR) - Company Net Income|Net Income upstreambio.com|Company Net Income Zenas Biopharma|Net Income Gossamer Bio Inc (GOSS)|Net Income KALV (KalVista Pharmaceuticals Inc)|Net Profit Septerna Pharma (SEPN)|Company Net Income Pieris Pharmaceuticals PVLA|SVRA: Company Profit|RIGL - Company Net Income|Company Net Income AnaptysBio Inc|Astria Pharma (ATXS) - Company Net Income|Net Income enGene Corp|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Company Net Income Aerovate JBIO|Net Income ACRS (Aclaris Therapeutics, Inc.)|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Net Financial Result Cabaletta Bio Inc (CABA)|VTYX - Company Net Income|THTX (theratech.com) - Company Profit|AVTX: Net Profit|Net Income Eledon Pharmaceuticals Inc.|Net Income AGEN|Climb Bio, Inc (CLYM) - Net Financial Result|Net Profit ZURA|Net Financial Result atyrpharma.com|Company Net Income Adagene Inc. ADAG|IMA - Net Income|STTK - Company Net Income|EQ (Equillium, Inc.) - Company Profit|connectbiopharm.com (CNTB) - Company Net Income|Net Income Immunic|Company Net Income Atara Biotherapeutics, Inc.|InflaRx GmbH - Profit After Tax|Net Profit XFOR|ACET (adicetbio.com) - Final Profit|Net Profit CELU (Celularity)|Net Profit inmunebio.com INMB|BRNS - Company Net Income|Final Profit KZR (Kezar Life Sciences Inc.)|SAB Biotherapeutics, Inc (SABS) - Company Net Income|Net Income Akari Therapeutics, Plc|ENLV (Enlivex Therapeutics Ltd) - Net Profit|Net Profit Q32 Bio Corp|Net Income GOVX (GeoVax)|EDSA (Edesa Biotech Inc) - Final Profit|Net Profit IBIO (iBio Corp)|Net Financial Result Carisma Therapeutics Inc (CARM)|XTLB - Company Net Income|Bolt Biotherapeutics (BOLT) - Net Income|hcwbiologics.com (HCWB) - Company Net Income|Net Income Aptevo Therapeutics Inc.|Net Income AIM|Net Profit Aditxt Corp|Company Net Income GRI Bio, Inc. (GRI)|xortx.com - Company Profit|Net Profit HIND (Vyome Holdings)|Revelation Biosciences Inc (REVB) - Company Net Income|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|THRD - Company Net Income